Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Interplay of TP53, ESR2 May Expand Treatment Options for Some TNBCs

Key clinical point: In triple-negative breast cancer, TP53 mutational status influences the prognostic impact of estrogen receptor-beta (ESR2) expression.

Major finding: High ESR2 expression was associated with better overall survival among women with mutant TP53 tumors (hazard ratio for death, 0.26) but a trend toward poorer overall survival among women with wild-type TP53 tumors (P = .05).

Study details: In vitro study and retrospective cohort study of 354 women with basal-like triple-negative breast cancer.

Disclosures: The authors disclosed that they had no conflicts of interest. The study was supported by the several sources including the National Cancer Institute and Susan G. Komen for the Cure.


Mukhopadhyay UK et al. J Natl Cancer Inst 2019 Apr 16 doi: 10.1093/jnci/djz051.